Autores
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Tjoung-Won Park-Simon, Gordon Rustin, Florence Joly, Mansoor R Mirza, Marie Plante, Michael Quinn, Andrés Poveda, Gordon C Jayson, Dan Stark, Ann Marie Swart, Laura Farrelly, Richard Kaplan, Mahesh KB Parmar, Timothy J Perren, ICON7 Trial Investigators
Fecha de publicación
2015/8/1
Revista
The Lancet Oncology
Volumen
16
Número
8
Páginas
928-936
Editor
Elsevier
Descripción
Background
The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the trial.
Methods
ICON7 was an international, phase 3, open-label, randomised trial undertaken at 263 centres in 11 countries across Europe, Canada, Australia and New Zealand. Eligible adult women with newly diagnosed ovarian cancer that was either high-risk early-stage disease (International Federation of Gynecology and Obstetrics [FIGO] stage I–IIa, grade 3 or clear cell histology) or more advanced disease (FIGO stage IIb–IV), with an Eastern Cooperative Oncology Group performance status of 0–2, were enrolled and randomly assigned in a 1:1 ratio to standard chemotherapy (six 3-weekly cycles of intravenous …
Artículos de Google Académico
AM Oza, AD Cook, J Pfisterer, A Embleton… - The Lancet Oncology, 2015